1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Preclinical Development (PDEV) program is sponsored by California Institute for Regenerative Medicine (CIRM). The PDEV program supports preclinical development of stem cell-based and genetic therapies that offer potential for transformative clinical impact and address current barriers to patient access.
This includes research on stem cell-derived retinal pigment epithelium (RPE) cells for treating maculopathies and supporting photoreceptors.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Researchers and institutions engaged in preclinical development of stem cell-based and genetic therapies. UCLA investigators considering a CIRM application are strongly encouraged to engage early with the UCLA Alpha Clinic. Confirm the full requirements in the official notice before applying.
The published deadline was October 1, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Preclinical Development (PDEV) program is funded by California Institute for Regenerative Medicine (CIRM). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
On September 29, 2026, USDA raised the Regenerative Pilot Program to $1 billion for FY 2027: $650 million through EQIP, $350 million through CSP. The headline is the money. The decisive change is CSP's resource-concern threshold dropping from 100 percent to 75 percent, and the fact that EQIP absorbed nearly all the growth.
Read articleOn September 17, 2026 the District of Massachusetts vacated the Education Department's February 5, 2025 anti-DEI directive government-wide, finding it arbitrary and capricious and contrary to three separate bodies of law. The vacatur is sweeping. The path to recovering $600 million runs through a different courthouse entirely.
Read articleDARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read article